Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022
May 05 2022 - 7:00AM
Business Wire
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical
company using its proprietary RADR® artificial intelligence
("A.I.") and machine learning (ML) platform to transform the cost,
pace, and timeline of oncology drug discovery and development,
today announced that the Company’s management will be speaking at
five investor and scientific conferences in May 2022.
Dr. Kishor Bhatia, Lantern’s Chief Scientific Officer, will be
speaking at the 9th Drug Discovery Strategic Summit on May 9th, and
presenting on the synthetic lethality potential of Lantern’s drug
candidates. Additionally, Panna Sharma, Lantern’s Chief Executive
Officer and President, will be speaking at four events in May,
including the Strategic Investment Conference on May 13th, the
MedVentures Conference on May 18th, the Augmented Intelligence in
Drug Discovery Xchange East Coast on May 19th, and the
Bioinformatics Strategy Meeting East Coast USA on May 23rd.
Further information on these conferences and events, including
registration links, can be found below:
9th Drug Discovery Strategic Summit Presentation
Information: May 9th, 2022 / 4:40 p.m. ET / Boston, MA
Presenter: Kishor Bhatia, Ph.D. Registration Link:
https://ddss.agilefalconsg.com/register-now/
Strategic Investment Conference 2022 Presentation
Information: May 13th, 2022 / 2:45 p.m. ET / Virtual
Presenter: Panna Sharma Registration Link:
https://www.mauldineconomics.com/sic-2022/#orderform
MedVentures Conference Presentation Information: May
18th, 2022 / 9:30-10:30 a.m. CT / Dallas, TX Presenter:
Panna Sharma Registration Link:
https://www.eventbrite.com/e/medventures-conference-2022-tickets-276088627517
Augmented Intelligence in Drug Discovery Xchange East Coast
Presentation Information: May 19th, 2022 / 9:05 a.m. ET /
Woburn, MA Presenter: Panna Sharma Registration Link:
https://www.hub-xchange.com/augmented-intelligence-in-drug-delivery-xchange-east-coast-2022/#anchor1
Bioinformatics Strategy Meeting East Coast USA 2022
Presentation Information: May 23rd, 2022 / 3:50 & 4:50
p.m. ET / Cambridge, MA Presenter: Panna Sharma
Registration Link:
https://proventainternational.com/events/rd/usa-east/boston/bioinformatics-strategy-meeting-east-coast-usa-2022/
About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is a
clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. and machine learning platform
to discover biomarker signatures that identify patients most likely
to respond to its pipeline of genomically targeted therapeutics.
Lantern is currently developing four drug candidates and an ADC
program across nine disclosed tumor targets, including two phase 2
programs. By targeting drugs to patients whose genomic profile
identifies them as having the highest probability of benefiting
from the drug, Lantern's approach represents the potential to
deliver best-in-class outcomes.
Please find more information at:
Website: www.lanternpharma.com LinkedIn:
https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma
Forward-looking Statements This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of our drug
candidates and antibody drug conjugate (ADC) development program;
estimates regarding the development timing for our drug candidates
and ADC development program; our research and development efforts
of our internal drug discovery programs and the utilization of our
RADR® platform to streamline the drug development process; our
intention to leverage artificial intelligence, machine learning and
genomic data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding potential markets and potential market sizes;
sales estimates for our drug candidates and our plans to discover
and develop drug candidates and to maximize their commercial
potential by advancing such drug candidates ourselves or in
collaboration with others. Any statements that are not statements
of historical fact (including, without limitation, statements that
use words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "objective," "aim,"
"upcoming," "should," "will," "would," or the negative of these
words or other similar expressions) should be considered
forward-looking statements. There are a number of important factors
that could cause our actual results to differ materially from those
indicated by the forward-looking statements, such as (i) the impact
of the COVID-19 pandemic, (ii) the risk that our research and the
research of our collaborators may not be successful, (iii) the risk
that none of our product candidates has received FDA marketing
approval, and we may not be able to successfully initiate, conduct,
or conclude clinical testing for or obtain marketing approval for
our product candidates, (iv) the risk that no drug product based on
our proprietary RADR® A.I. platform has received FDA marketing
approval or otherwise been incorporated into a commercial product,
and (v) those other factors set forth in the Risk Factors section
in our Annual Report on Form 10-K for the year ended December 31,
2021, filed with the Securities and Exchange Commission on March
10, 2022. You may access our Annual Report on Form 10-K for the
year ended December 31, 2021 under the investor SEC filings tab of
our website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220505005312/en/
Lantern’s Investor Relations Contact: Nicole Leber Investor
Relations Associate ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024